Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers
This study has been completed.
Sponsor:
University of Minnesota - Clinical and Translational Science Institute
Collaborator:
Tate and Lyle Ingredients France
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT00958399
First received: August 12, 2009
Last updated: February 3, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Research suggests dietary fiber may play a role in weight management, and fiber consumption is inversely associated with body weight, body fat, and BMI in cross-sectional studies. These effects may be mediated by increased satiety, reduced food intake, or changes in blood levels of glucose, insulin, and gut hormones.
The purpose of this study is to determine the satiety, glycemic, hormonal, and gastrointestinal responses of novel fiber supplements.
| Condition | Intervention |
|---|---|
|
Healthy |
Dietary Supplement: Placebo Dietary Supplement: Resistant Starch Dietary Supplement: Resistant starch + soluble fiber Dietary Supplement: Fiber made from corn starch Dietary Supplement: Fiber made from corn starch + soluble fiber |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) |
| Official Title: | Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers |
Resource links provided by NLM:
Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:
Primary Outcome Measures:
- Satiety [ Time Frame: 0, 15, 30, 45, 60, 90, 120, 180, 215 minutes postprandially ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- ad libitum food intake [ Time Frame: 180 minutes postprandially and over 24 hours ] [ Designated as safety issue: No ]
- Ghrelin, polypeptide YY (PYY), and glucagon-like peptide-1 (GLP-1) response [ Time Frame: 0, 30, 60 minutes postprandially ] [ Designated as safety issue: No ]
- Gastrointestinal tolerance and fecal chemistry [ Time Frame: following 7 days of treatment ] [ Designated as safety issue: No ]
- Glucose/Insulin Response [ Time Frame: 0, 15, 30, 45, 60, 90, 120, 180 minutes postprandially ] [ Designated as safety issue: No ]
| Enrollment: | 20 |
| Study Start Date: | July 2008 |
| Study Completion Date: | April 2010 |
| Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: No fiber
No fiber added to study products
|
Dietary Supplement: Placebo
Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
|
|
Experimental: Resistant Starch
Muffins, cereal, and bars made with a resistant starch
|
Dietary Supplement: Resistant Starch
25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
|
|
Experimental: Resistant starch + soluble fiber
Muffins, cereal, and bars made with a mixture of resistant starch and a soluble fiber
|
Dietary Supplement: Resistant starch + soluble fiber
25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
|
|
Experimental: Fiber made from corn starch
Muffins, cereal, and bars made with novel corn fiber
|
Dietary Supplement: Fiber made from corn starch
25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
|
|
Experimental: Fiber made from corn starch + soluble fiber
Muffins, cereal, and bars made with a mixture of novel corn fiber and a soluble fiber
|
Dietary Supplement: Fiber made from corn starch + soluble fiber
25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
|
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- healthy men and women
- age 18-60 years
- non-smoking
- not taking medication
- non-dieting (weight stable in prior 3 months)
- BMI 18-27
- English literacy
- ability to give blood
Exclusion Criteria:
- do not regularly consume breakfast
- food allergies to ingredients found in study products
- dislike for muffins, fiber bars, or hot cereal
- BMI <18 or >27
- diagnosed cardiovascular, renal, or hepatic disease
- diabetes mellitus (fasting blood sugar >126 mg/dl)
- cancer in previous 5 years (except basal cell carcinoma of the skin)
- any gastrointestinal disease or condition
- recent bacterial infection (< 3 months)
- recent or concurrent participation in an intervention research study
- history of drug or alcohol abuse in prior 6 months
- use of lipid-lowering, anti-hypertensive, or anti-inflammatory steroid medication
- restrained eaters
- vegetarians
- people who eat more than approximately 15 grams of fiber per day
- women who are pregnant or lactating
- women with irregular menstrual cycles
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00958399
Locations
| United States, Minnesota | |
| University of Minnesota - General Clinical Research Center | |
| Minneapolis, Minnesota, United States, 55455 | |
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Tate and Lyle Ingredients France
Investigators
| Principal Investigator: | Joanne L Slavin, PhD | University of Minnesota - Clinical and Translational Science Institute |
More Information
No publications provided by University of Minnesota - Clinical and Translational Science Institute
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University of Minnesota - Clinical and Translational Science Institute |
| ClinicalTrials.gov Identifier: | NCT00958399 History of Changes |
| Other Study ID Numbers: | 0701M00264 |
| Study First Received: | August 12, 2009 |
| Last Updated: | February 3, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
|
satiety fiber food intake |
gut hormones visual analog scales microflora |
ClinicalTrials.gov processed this record on May 16, 2013